Next Article in Journal
Multi-Elemental Profiling of Tibial and Maxillary Trabecular Bone in Ovariectomised Rats
Next Article in Special Issue
Endometriosis Might Be Inversely Associated with Developing Chronic Kidney Disease: A Population-Based Cohort Study in Taiwan
Previous Article in Journal
Rhizobacterial Strain Bacillus megaterium BOFC15 Induces Cellular Polyamine Changes that Improve Plant Growth and Drought Resistance
Previous Article in Special Issue
Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
Open AccessReview

Role of mTOR Inhibitors in Kidney Disease

Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Alan Parrish
Int. J. Mol. Sci. 2016, 17(6), 975; https://doi.org/10.3390/ijms17060975
Received: 29 April 2016 / Revised: 13 June 2016 / Accepted: 16 June 2016 / Published: 21 June 2016
(This article belongs to the Special Issue Advances in Chronic Kidney Disease)
The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui). Because sirolimus showed antiproliferative activity, researchers investigated its molecular target and identified the TOR1 and TOR2. The mTOR consists of mTOR complex 1 (mTORC1) and mTORC2. Rapalogues including sirolimus, everolimus, and temsirolimus exert their effect mainly on mTORC1, whereas their inhibitory effect on mTORC2 is mild. To obtain compounds with more potent antiproliferative effects, ATP-competitive inhibitors of mTOR targeting both mTORC1 and mTORC2 have been developed and tested in clinical trials as anticancer drugs. Currently, mTOR inhibitors are used as anticancer drugs against several solid tumors, and immunosuppressive agents for transplantation of various organs. This review discusses the role of mTOR inhibitors in renal disease with a particular focus on renal cancer, diabetic nephropathy, and kidney transplantation. View Full-Text
Keywords: mTOR inhibitor; kidney; renal cancer; diabetic nephropathy; kidney transplantation mTOR inhibitor; kidney; renal cancer; diabetic nephropathy; kidney transplantation
Show Figures

Figure 1

MDPI and ACS Style

Kajiwara, M.; Masuda, S. Role of mTOR Inhibitors in Kidney Disease. Int. J. Mol. Sci. 2016, 17, 975.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop